Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Baxter International Inc. stock logo
BAX
Baxter International
$30.03
+0.8%
$30.31
$26.25
$40.49
$15.39B0.614.40 million shs5.60 million shs
DexCom, Inc. stock logo
DXCM
DexCom
$80.00
-1.2%
$80.08
$57.52
$117.19
$31.37B1.464.36 million shs5.24 million shs
Insulet Corporation stock logo
PODD
Insulet
$303.15
+0.5%
$291.86
$173.00
$329.33
$21.33B1.37715,791 shs1.54 million shs
ResMed Inc. stock logo
RMD
ResMed
$253.65
+1.1%
$240.71
$179.42
$263.05
$37.20B0.78998,267 shs964,317 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Baxter International Inc. stock logo
BAX
Baxter International
0.00%-1.88%-0.81%-9.60%-10.98%
DexCom, Inc. stock logo
DXCM
DexCom
0.00%-2.43%-5.69%+8.40%-31.41%
Insulet Corporation stock logo
PODD
Insulet
0.00%-0.49%-5.56%+12.98%+54.35%
ResMed Inc. stock logo
RMD
ResMed
0.00%+1.80%+3.33%+15.42%+19.50%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Baxter International Inc. stock logo
BAX
Baxter International
4.3096 of 5 stars
2.23.01.74.02.01.72.5
DexCom, Inc. stock logo
DXCM
DexCom
4.8322 of 5 stars
3.55.00.04.72.72.51.9
Insulet Corporation stock logo
PODD
Insulet
4.3956 of 5 stars
2.45.00.04.92.80.81.9
ResMed Inc. stock logo
RMD
ResMed
4.0923 of 5 stars
2.31.03.34.62.61.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Baxter International Inc. stock logo
BAX
Baxter International
2.44
Hold$37.2524.06% Upside
DexCom, Inc. stock logo
DXCM
DexCom
2.95
Moderate Buy$98.5023.13% Upside
Insulet Corporation stock logo
PODD
Insulet
2.83
Moderate Buy$321.005.89% Upside
ResMed Inc. stock logo
RMD
ResMed
2.60
Moderate Buy$259.332.24% Upside

Current Analyst Ratings Breakdown

Latest RMD, PODD, BAX, and DXCM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/16/2025
DexCom, Inc. stock logo
DXCM
DexCom
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$102.00
6/16/2025
Insulet Corporation stock logo
PODD
Insulet
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$365.00
5/30/2025
DexCom, Inc. stock logo
DXCM
DexCom
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$104.00
5/30/2025
Insulet Corporation stock logo
PODD
Insulet
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$380.00
5/27/2025
Insulet Corporation stock logo
PODD
Insulet
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$328.00 ➝ $360.00
5/22/2025
DexCom, Inc. stock logo
DXCM
DexCom
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$82.00 ➝ $102.00
5/22/2025
Insulet Corporation stock logo
PODD
Insulet
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$320.00 ➝ $380.00
5/20/2025
ResMed Inc. stock logo
RMD
ResMed
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOverweight ➝ Overweight$286.00
5/16/2025
Insulet Corporation stock logo
PODD
Insulet
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
5/13/2025
Insulet Corporation stock logo
PODD
Insulet
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$350.00
5/9/2025
Insulet Corporation stock logo
PODD
Insulet
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$312.00 ➝ $324.00
(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Baxter International Inc. stock logo
BAX
Baxter International
$10.64B1.45$4.76 per share6.31$13.76 per share2.18
DexCom, Inc. stock logo
DXCM
DexCom
$4.03B7.78$2.25 per share35.59$5.38 per share14.87
Insulet Corporation stock logo
PODD
Insulet
$2.07B10.30$4.44 per share68.33$17.27 per share17.55
ResMed Inc. stock logo
RMD
ResMed
$4.69B7.94$9.23 per share27.49$33.11 per share7.66
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Baxter International Inc. stock logo
BAX
Baxter International
-$649M-$1.10N/A11.000.88-4.71%17.24%5.12%8/5/2025 (Estimated)
DexCom, Inc. stock logo
DXCM
DexCom
$576.20M$1.3459.7032.521.7112.90%30.05%10.00%7/24/2025 (Estimated)
Insulet Corporation stock logo
PODD
Insulet
$418.30M$5.5654.5261.002.7118.29%22.25%8.29%8/6/2025 (Estimated)
ResMed Inc. stock logo
RMD
ResMed
$1.02B$8.9128.4724.481.7526.15%25.67%18.59%7/30/2025 (Estimated)

Latest RMD, PODD, BAX, and DXCM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Insulet Corporation stock logo
PODD
Insulet
$0.81$1.02+$0.21$0.50$543.20 million$569.00 million
5/1/2025Q1 2025
Baxter International Inc. stock logo
BAX
Baxter International
$0.48$0.62+$0.14$0.25$2.59 billion$2.63 billion
5/1/2025Q1 2025
DexCom, Inc. stock logo
DXCM
DexCom
$0.33$0.32-$0.01$0.27$1.02 billion$1.04 billion
4/23/2025Q3 2025
ResMed Inc. stock logo
RMD
ResMed
$2.36$2.37+$0.01$2.48$1.28 billion$1.29 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Baxter International Inc. stock logo
BAX
Baxter International
$0.682.26%N/AN/A N/A
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
Insulet Corporation stock logo
PODD
Insulet
N/AN/AN/AN/AN/A
ResMed Inc. stock logo
RMD
ResMed
$2.120.84%N/A23.79%13 Years

Latest RMD, PODD, BAX, and DXCM Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/6/2025
Baxter International Inc. stock logo
BAX
Baxter International
quarterly$0.172.27%5/30/20255/30/20257/1/2025
4/24/2025
ResMed Inc. stock logo
RMD
ResMed
quarterly$0.530.9%5/8/20255/8/20256/12/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Baxter International Inc. stock logo
BAX
Baxter International
1.33
2.02
1.40
DexCom, Inc. stock logo
DXCM
DexCom
0.55
1.50
1.32
Insulet Corporation stock logo
PODD
Insulet
1.21
4.47
3.63
ResMed Inc. stock logo
RMD
ResMed
0.12
3.41
2.49

Institutional Ownership

CompanyInstitutional Ownership
Baxter International Inc. stock logo
BAX
Baxter International
90.19%
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
Insulet Corporation stock logo
PODD
Insulet
N/A
ResMed Inc. stock logo
RMD
ResMed
54.98%

Insider Ownership

CompanyInsider Ownership
Baxter International Inc. stock logo
BAX
Baxter International
0.20%
DexCom, Inc. stock logo
DXCM
DexCom
0.32%
Insulet Corporation stock logo
PODD
Insulet
0.39%
ResMed Inc. stock logo
RMD
ResMed
0.71%
CompanyEmployeesShares OutstandingFree FloatOptionable
Baxter International Inc. stock logo
BAX
Baxter International
38,000513.17 million512.15 millionOptionable
DexCom, Inc. stock logo
DXCM
DexCom
10,300392.11 million390.85 millionOptionable
Insulet Corporation stock logo
PODD
Insulet
3,90070.38 million70.10 millionOptionable
ResMed Inc. stock logo
RMD
ResMed
9,980146.63 million145.59 millionOptionable

Recent News About These Companies

ResMed: A Sleeping Giant Hiding In Plain Sight

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Baxter International stock logo

Baxter International NYSE:BAX

$30.02 +0.23 (+0.76%)
Closing price 06/20/2025 03:59 PM Eastern
Extended Trading
$30.03 +0.01 (+0.02%)
As of 06/20/2025 06:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

DexCom stock logo

DexCom NASDAQ:DXCM

$80.00 -1.01 (-1.25%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$79.98 -0.02 (-0.02%)
As of 06/20/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Insulet stock logo

Insulet NASDAQ:PODD

$303.15 +1.36 (+0.45%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$303.14 -0.01 (0.00%)
As of 06/20/2025 07:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

ResMed stock logo

ResMed NYSE:RMD

$253.65 +2.77 (+1.11%)
Closing price 06/20/2025 03:59 PM Eastern
Extended Trading
$254.62 +0.97 (+0.38%)
As of 06/20/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.